Vanda Pharmaceuticals Inc. (VNDA)

Over the past six months, Vanda Pharmaceuticals' stock has experienced several events and trends. As of October 23, 2025, the share price was $5.49, representing an increase of 21.46% from October 24, 2024. In Q2 2025, Vanda reported a net loss of $27.2 million, compared to a net loss of $4.5 million in Q2 2024. Total revenues for Q2 2025 were $52.6 million, a 4% increase compared to Q2 2024. Vanda reiterated its 2025 financial guidance, expecting total revenue between $210 million and $250 million, and year-end 2025 cash of $280 million to $320 million. In October 2025, Vanda announced a collaborative framework for the resolution of disputes with the U.S. Food and Drug Administration (FDA). In May 2025, Vanda Pharmaceuticals reported a Q1 loss but topped revenue estimates. In February 2025, Vanda Pharmaceuticals reported a net loss of $18.9 million for 2024, compared to a net income of $2.5 million in 2023. The company has faced ongoing patent litigation concerning HETLIOZ, with generic versions entering the market following unfavorable court rulings, impacting sales. Vanda's management's rejection of buyout offers and ongoing disputes with the FDA have raised concerns about its decision-making and market perception, despite strong financials.

The provided search results do not contain specific information regarding the demand seasonality for Vanda Pharmaceuticals Inc.'s products and services. However, the company's revenue guidance for 2025 anticipates revenue to be "back-weighted", with Fanapt and PONVORY in early commercial launch, and Fanapt expected to grow on a quarterly basis with accelerating trajectory later in the year and into the next year. This suggests that while overall demand might not have strong seasonal fluctuations, the commercial ramp-up of newer products could create a pattern of increasing sales throughout the year.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and rare diseases. The company's commercial portfolio includes HETLIOZ® (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, Fanapt® (iloperidone) for schizophrenia and bipolar I disorder, and PONVORY® (ponesimod) for relapsing forms of multiple sclerosis. The company also has a pipeline of products under development, including Tradipitant (VLY-686) for gastroparesis, motion sickness, and atopic dermatitis; VTR-297; VQW-765; and a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors and activators.

Vanda Pharmaceuticals primarily sells its products in the United States. The company also has a geographic presence in Israel, Europe, and Canada.

Vanda Pharmaceuticals maintains scientific credibility through research dissemination. However, the company's reputation has been impacted by ongoing disputes with the FDA. These legal and regulatory challenges could affect public and investor perception of the company.

Vanda Pharmaceuticals Inc. has a diverse ownership base, primarily dominated by institutional investors. Approximately 76.17% of Vanda Pharmaceuticals is owned by institutional shareholders. Insiders own approximately 68.92% of Vanda Pharmaceuticals. James E. Flynn is the largest individual shareholder, owning 8.67 million shares, representing 14.67% of the company.